BRPI0807952A2 - Sistemas de hipermutação somática - Google Patents

Sistemas de hipermutação somática

Info

Publication number
BRPI0807952A2
BRPI0807952A2 BRPI0807952-8A2A BRPI0807952A BRPI0807952A2 BR PI0807952 A2 BRPI0807952 A2 BR PI0807952A2 BR PI0807952 A BRPI0807952 A BR PI0807952A BR PI0807952 A2 BRPI0807952 A2 BR PI0807952A2
Authority
BR
Brazil
Prior art keywords
somatic hypermutation
systems
hypermutation systems
somatic
hypermutation
Prior art date
Application number
BRPI0807952-8A2A
Other languages
English (en)
Inventor
Robert A Horlick
Andrew B Cubitt
Peter M Bowers
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of BRPI0807952A2 publication Critical patent/BRPI0807952A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0807952-8A2A 2007-02-20 2008-02-20 Sistemas de hipermutação somática BRPI0807952A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90241407P 2007-02-20 2007-02-20
US90462207P 2007-03-01 2007-03-01
US99597007P 2007-09-28 2007-09-28
US2012408P 2008-01-09 2008-01-09
PCT/US2008/002397 WO2008103475A1 (en) 2007-02-20 2008-02-20 Somatic hypermutation systems

Publications (1)

Publication Number Publication Date
BRPI0807952A2 true BRPI0807952A2 (pt) 2014-06-10

Family

ID=39710412

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807952-8A2A BRPI0807952A2 (pt) 2007-02-20 2008-02-20 Sistemas de hipermutação somática

Country Status (8)

Country Link
US (7) US8603950B2 (pt)
EP (2) EP2126105A4 (pt)
JP (3) JP2010520748A (pt)
AU (1) AU2008218925A1 (pt)
BR (1) BRPI0807952A2 (pt)
CA (1) CA2678451A1 (pt)
NZ (1) NZ579010A (pt)
WO (2) WO2008103475A1 (pt)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP1974017B2 (en) 2005-12-09 2023-06-21 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
JP2010538655A (ja) * 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CA2739663A1 (en) 2008-10-10 2010-05-15 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
CN102482639B (zh) 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
US20110082055A1 (en) * 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
EP3301208B1 (en) * 2009-09-18 2020-11-04 Codexis, Inc. Reduced codon mutagenesis
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
WO2011056864A1 (en) * 2009-11-05 2011-05-12 Anaptysbio, Inc. Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation
JP2011182645A (ja) * 2010-03-04 2011-09-22 Kyushu Univ 動物細胞ディスプレイ法およびそれを利用した完全ヒトモノクローナル抗体の体外成熟法
CN102409042B (zh) * 2010-09-21 2014-05-14 深圳华大基因科技服务有限公司 一种高通量基因组甲基化dna富集方法及其所使用标签和标签接头
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2647704B1 (en) 2010-12-01 2017-11-01 Mitsubishi Tanabe Pharma Corporation Polynucleotide construct capable of presenting fab in acellular translation system, and method for manufacturing and screening fab using same
EP2646466B1 (en) 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2670848B1 (en) 2011-02-06 2016-02-03 Yeda Research and Development Co. Ltd Affinity maturated t cell receptors and use thereof
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US20130102031A1 (en) * 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20150018380A1 (en) * 2012-02-07 2015-01-15 University Of Rochester Methods of Screening for Activation Deaminase Inhibitors Through Nuclear Import Inhibitors
CA2860600C (en) * 2012-02-15 2022-07-26 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
TWI619727B (zh) * 2013-02-27 2018-04-01 中央研究院 抗體之原位親和力成熟作用
US10101337B2 (en) 2013-03-14 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies
CA2940322C (en) * 2014-02-21 2021-05-18 President And Fellows Of Harvard College De novo design of allosteric proteins
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
MX383150B (es) 2014-06-02 2025-03-13 Us Health Receptores quiméricos de antígeno que tienen como diana a cd-19.
RS59340B1 (sr) 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
EA201792184A1 (ru) 2015-04-01 2018-04-30 Анаптисбайо, Инк. Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
EP3283512A4 (en) * 2015-04-17 2018-10-03 Distributed Bio Inc Method for mass humanization of non-human antibodies
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
JP7023842B2 (ja) * 2015-10-29 2022-02-22 テンプル ユニヴァーシティ － オブ ザ コモンウェルス システム オブ ハイアー エデュケーション Ｄｎａポリメラーゼシータによる核酸の３’末端の修飾
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
GB201521447D0 (en) * 2015-12-04 2016-01-20 Ucb Biopharma Sprl De novo antibody design
CN118185874A (zh) * 2016-04-04 2024-06-14 苏黎世联邦理工学院 一种重组哺乳动物b细胞
US11401527B2 (en) 2016-04-17 2022-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods useful for prophylaxis of organophosphates
WO2017210149A1 (en) * 2016-05-31 2017-12-07 Igc Bio, Inc. Compositions and methods for generating an antibody library
SG11201810640RA (en) 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
GB2553274A (en) * 2016-07-29 2018-03-07 Nuclera Nucleics Ltd Novel use
WO2018035159A1 (en) 2016-08-15 2018-02-22 Enevolv, Inc. Molecule sensor systems
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
KR20190102259A (ko) 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3052487A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
US20180282721A1 (en) * 2017-03-15 2018-10-04 Twist Bioscience Corporation De novo synthesized combinatorial nucleic acid libraries
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
EP3635132A4 (en) 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US10174295B1 (en) * 2017-08-01 2019-01-08 The Charles Stark Draper Laboratory, Inc. Composition of matter: engineering of Escherichia coli phage K1E
US10988546B2 (en) 2017-08-01 2021-04-27 Medimmune, Llc BCMA monoclonal antibody-drug conjugate
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
EP3694877A1 (en) 2017-10-09 2020-08-19 AnaptysBio, Inc. Anti-il-33 therapy for atopic dermatitis
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
WO2019173465A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
TW202021983A (zh) 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
EP3856773A1 (en) 2018-09-28 2021-08-04 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN109325017B (zh) * 2018-10-25 2022-03-04 中国辐射防护研究院 一种放射性核素迁移扩散数值模拟系统的数据库设计方法
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
US20220235132A1 (en) 2019-06-05 2022-07-28 Anaptysbio, Inc. Pd-1 agonist and method of using same
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
EP4031172A4 (en) * 2019-09-16 2024-02-21 Chen, Dalu METHOD FOR BLOCKING ASV INFECTION BY DISRUPTING CELL RECEPTORS
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Ｃｒｔｈ２のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
AU2020378263A1 (en) 2019-11-05 2022-06-23 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
WO2021186398A1 (en) 2020-03-19 2021-09-23 Medimmune Limited Anti-klebsiella pneumoniae antibodies and uses thereof
WO2021247761A1 (en) * 2020-06-02 2021-12-09 University Of Southern California Methods and compositions for in vitro affinity maturation of monoclonal antibodies
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
JP2023536851A (ja) 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
EP4188960A4 (en) 2020-08-03 2024-09-11 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022087441A2 (en) 2020-10-23 2022-04-28 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2022116086A1 (en) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023081752A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
CN114264821B (zh) * 2021-12-24 2024-04-26 江南大学 检测新型冠状病毒中和抗体的试剂盒及其制备方法与应用
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
AU2023223523A1 (en) 2022-02-28 2024-09-26 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023196933A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
KR20250007603A (ko) 2022-04-27 2025-01-14 아납티스바이오, 아이엔씨. B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법
CA3262035A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
WO2024050457A1 (en) 2022-08-31 2024-03-07 Boost Biopharma, Inc. Sars-cov-2 binding agents and uses thereof
WO2024062161A1 (en) 2022-09-21 2024-03-28 Orion Corporation Antibody discovery and development method
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
JP2025537224A (ja) 2022-11-07 2025-11-14 アナプティスバイオ インコーポレイティッド Ｃｄ１２２結合剤およびその使用方法
WO2024191919A1 (en) 2023-03-10 2024-09-19 The Regents Of The University Of Colorado, A Body Corporate Anti-cd56 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
AU2024236108A1 (en) 2023-03-10 2025-09-25 The Regents Of The University Of Colorado, A Body Corporate Anti-cd276 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
WO2024206856A2 (en) * 2023-03-30 2024-10-03 Thomas Jefferson University Dna-dependent synthesis of rna by dna polymerase theta variants
CA3205511A1 (en) 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2024243594A1 (en) 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
GB202309512D0 (en) 2023-06-23 2023-08-09 Astrazeneca Ab Lilrb2 binding proteins and uses thereof
WO2025032508A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Enpp3 and cd3 binding agents and methods of use thereof
WO2025126102A1 (en) 2023-12-12 2025-06-19 Janssen Biotech, Inc. Enpp3 × cd3 bispecific antibodies and use thereof
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
US20250269024A1 (en) 2024-02-05 2025-08-28 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20250339527A1 (en) 2024-03-12 2025-11-06 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025251015A1 (en) 2024-05-30 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pan-gi norovirus monoclonal antibody and its use
WO2026033437A1 (en) 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026060381A1 (en) 2024-09-13 2026-03-19 Anaptysbio, Inc. Cd 122 binding agents for inhibiting an immune response in celiac disease or related conditions

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183661B (en) * 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5583024A (en) * 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5221623A (en) 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5070012A (en) 1988-03-30 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Monitoring of cells and trans-activating transcription elements
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
FR2685004A1 (fr) 1991-12-11 1993-06-18 Pasteur Institut Procede de generation d'une diversite structurale et fonctionnelle dans une sequence peptidique.
US5750335A (en) * 1992-04-24 1998-05-12 Massachusetts Institute Of Technology Screening for genetic variation
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
US5855827A (en) * 1993-04-14 1999-01-05 Adroit Systems, Inc. Pulse detonation synthesis
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6027877A (en) 1993-11-04 2000-02-22 Gene Check, Inc. Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, purification of amplified DNA samples and allele identification
NZ281023A (en) 1994-01-27 1998-04-27 Human Genome Sciences Inc Human dna mismatch repair proteins and coding sequences
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
JP3466765B2 (ja) 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
JP3659261B2 (ja) * 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
AU6410596A (en) 1995-07-31 1997-02-26 Centre De Recherche De L'hopital Sainte-Justine Cytidine deaminase cdna as a positive selectable marker for ene transfer, gene therapy and protein synthesis
AU725609C (en) * 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US5843757A (en) 1995-08-24 1998-12-01 The Johns Hopkins University Human JTV1 gene overlaps PMS2 gene
ZA967182B (en) 1995-08-24 1998-05-25 Magainin Pharma Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof
CN1291198A (zh) 1998-02-06 2001-04-11 伊来克萨斯独资有限公司 Fc受体的三维结构和模型及其应用
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
WO2000015214A1 (en) 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
US20020155453A1 (en) 1998-10-09 2002-10-24 Sale Julian Edward Method for generating diversity
DK1117774T3 (da) 1998-10-09 2010-05-03 Medical Res Council Fremgangsmåde til diversitetsgenerering
US7122339B2 (en) * 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
US20040038317A1 (en) 1999-03-15 2004-02-26 Kalobios, Inc. Breakpoint fusion fragment complementation system
AU3330700A (en) 1999-03-29 2000-10-16 Tasuku Honjo Novel cytidine deaminase
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
DK1180123T3 (da) * 1999-05-27 2008-10-13 Us Gov Health & Human Serv Immunkonjugater, der har höj bindingsaffinitet
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
AU2001226023A1 (en) * 2000-02-18 2001-08-27 Luigi Grasso A method for generating hypermutable plants
ATE351914T1 (de) 2000-02-23 2007-02-15 Univ Johns Hopkins Verfahren zur erzeugung von schnell mutierender hefe
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US6825038B2 (en) 2000-05-12 2004-11-30 The Johns Hopkins University Method for generating hypermutable organisms
FR2814642B1 (fr) * 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
US6808894B1 (en) 2000-11-07 2004-10-26 Morphotek, Inc. Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
US6576468B1 (en) 2000-11-07 2003-06-10 Morphotek, Inc. Methods for obtaining microbe-resistant mammalian cells from hypermutable mammalian cells
ATE423467T1 (de) 2000-11-07 2009-03-15 Morphotek Inc Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften
US6737268B1 (en) 2000-11-14 2004-05-18 Morphotek, Inc. Method for generating genetically altered antigens
US20030096401A1 (en) * 2000-11-28 2003-05-22 Huse William D. Eukaryotic expression libraries and methods of use
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US6723433B2 (en) 2001-03-02 2004-04-20 3M Innovative Properties Company Printable film and coating composition exhibiting stain resistance
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
DK1390535T3 (da) * 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
DK1401498T3 (da) 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
AU2002313716A1 (en) 2001-07-31 2003-02-17 University Of Medicine And Dentistry Of New Jersey Method of utilizing neurotrophins to manipulate reproductive capacity
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
AU2002336760A1 (en) 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
WO2003029473A1 (en) 2001-10-03 2003-04-10 The Regents Of The University Of California Genetic tagging strategy for inducing and identifying mutations in a genomic sequence
FR2833612B1 (fr) 2001-12-18 2006-01-27 Inst Necker Procede pour l'induction maitrisee de mutations somatiques et son application en proteomique
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
WO2003061363A2 (en) 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
JP2005531291A (ja) 2002-02-21 2005-10-20 モーフオテク・インコーポレーテツド Ｐｍｓｒ相同体を使用する超変異性細胞の作成方法
EP1506288B1 (en) * 2002-05-10 2013-04-17 Medical Research Council Activation induced deaminase (aid)
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
JP2004033137A (ja) * 2002-07-05 2004-02-05 Tasuku Honjo 抗癌剤のスクリーニング方法
US20040115695A1 (en) 2002-07-19 2004-06-17 Morphotek Inc. Methods for generating enhanced antibody producing cell lines with improved growth characteristics
WO2004029713A1 (ja) * 2002-09-30 2004-04-08 National Institute Of Advanced Industrial Science And Technology 超短レーザーパルス発生方法及び装置
EP1545615A4 (en) * 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
CA2506127C (en) 2002-11-15 2013-07-09 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
AU2002953381A0 (en) 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
WO2004072266A2 (en) * 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
CN102408483B (zh) * 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
US20050022686A1 (en) 2003-07-28 2005-02-03 Dreampatch, Llc Apparatus, method, and computer program product for animation pad transfer
AU2004261229A1 (en) 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US6957845B2 (en) * 2003-07-31 2005-10-25 Dana Corporation Space frame cross member with integrated door seal feature
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7604994B2 (en) 2003-09-03 2009-10-20 Morphotek, Inc. Genetically altered antibody-producing cell lines with improved antibody characteristics
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US7413737B2 (en) 2003-11-14 2008-08-19 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
JP2008504218A (ja) 2003-12-08 2008-02-14 モルフォテック、インク． Ｐｍｓ２と特異的に結合する抗体
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
JP2007523647A (ja) * 2004-02-05 2007-08-23 マサチューセッツ インスティテュート オブ テクノロジー 細胞ディスプレイライブラリー
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1568765A1 (en) 2004-02-23 2005-08-31 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for genetic diversification in gene conversion active cells
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2572961C (en) * 2004-07-06 2016-08-16 Bioren, Inc. Universal antibody libraries
US20060080745A1 (en) 2004-10-08 2006-04-13 Cornell Research Foundation, Inc. Gene reactivation by somatic hypermutation
US7393923B2 (en) * 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
US20060134098A1 (en) 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
JP5153613B2 (ja) * 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática

Also Published As

Publication number Publication date
US9637556B2 (en) 2017-05-02
EP2126105A1 (en) 2009-12-02
WO2008103474A1 (en) 2008-08-28
JP2010518859A (ja) 2010-06-03
JP2013220103A (ja) 2013-10-28
US20120028301A1 (en) 2012-02-02
WO2008103475A1 (en) 2008-08-28
US20090093024A1 (en) 2009-04-09
EP2126105A4 (en) 2010-11-03
JP2010520748A (ja) 2010-06-17
US8685897B2 (en) 2014-04-01
US20110287485A1 (en) 2011-11-24
US20090075378A1 (en) 2009-03-19
US20140170705A1 (en) 2014-06-19
US9260533B2 (en) 2016-02-16
CA2678451A1 (en) 2008-08-28
US20140094392A1 (en) 2014-04-03
US20110183855A1 (en) 2011-07-28
NZ579010A (en) 2012-03-30
JP5675109B2 (ja) 2015-02-25
US8603950B2 (en) 2013-12-10
EP2126087A1 (en) 2009-12-02
EP2126087A4 (en) 2010-10-27
AU2008218925A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
BRPI0807952A2 (pt) Sistemas de hipermutação somática
ATE481948T1 (de) Linseneinführsystem
BRPI0821019A2 (pt) Sistema de comunicação
ATE427720T1 (de) Linseneinfuhrsystem
FI20060131A0 (fi) Yhteysjärjestelmä
ATE431117T1 (de) Linseneinführsystem
DK2118055T3 (da) Antiparasitmidler
FI20075368L (fi) Oksasakset
EP2146804A4 (en) COATING SYSTEM
EP2227553A4 (en) Lac expression system
CR9342S (es) Regadera
DE602007009224D1 (de) R-cellular-systemen
DK1955639T3 (da) Rengøringssystem
EP2187651A4 (en) NETWORK SYSTEM
FI20075972A0 (fi) Tietoliikennejärjestelmä
IT1398018B1 (it) Obice rimorchiato
EP2211736C0 (en) EMBRYONIC CONTROL SYSTEM
NL2002066A1 (nl) Trailer.
DK2205488T3 (da) Sprøjteanlæg
NL1035129A1 (nl) Verlichtingssysteem.
SE0701400L (sv) Odlingssystem
AT506162A3 (de) Ablaufanlage
SE0701319L (sv) Ventilationssystem
ES1066323Y (es) Estaca de cultivo
FI7844U1 (fi) Yhteysjärjestelmä

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL